Five months after giving up on its lead drug Betalutin for follicular lymphoma, Nordic Nanovector has charted a course forward via a merger with fellow Norwegian biotech APIM Therapeutics. The merger ...
For months now, Nordic Nanovector has been on the hunt for any salvation that could stave off financial ruin after facing persistent clinical obstacles. And it appears that the company may have found ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback